The attraction of listing in the US for innovative companies is clear but the heads of the Swiss Biotech Association tell Scrip that start-ups should remember the advantages of playing at home and not waste too much energy and time on worrying about being on the NASDAQ.

The European Medicines Agency believes Idorsia’s Jeraygo should be approved for use in the EU at two different doses rather than just the one approved by the US Food and Drug Administration last month.

The CHMP, the European Medicines Agency’s human medicines committee, will this week decide whether a range of new medicines merit being approved.

CEO Jean-Paul Clozel insists Idorsia could launch the first-in-class hypertension drug alone, but analysts think a deal will be done soon – with the only question being for how much.